Is Liminatus Pharma, Inc. Warrants (LIMNW) overvalued?
Liminatus Pharma, Inc. Warrants (LIMNW) is a biotechnology company listed on US.
This page asks whether Liminatus Pharma, Inc. Warrants (LIMNW) looks expensive on cached numbers — not a short thesis.
No cached income statement for LIMNW, so there is no earnings base to call rich or cheap.
LIMNW currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LIMNW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LIMNW stock page for the full model, not this heading.
Not investment advice.